Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth ...

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...

Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO ...

Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk ...

Get Q3 2025 Pfizer earnings call insights—guidance raised, major acquisitions, regulatory updates, and R&D highlights.

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

Sen. Ruben Gallego (D-Ariz.) is raising concerns over the lack of details given about President Trump’s “most favored nation” (MFN) pricing deal he announced with Pfizer this week, calling on the ...

Pfizer CEO Albert Bourla appeared on ABC's "This Week." Pfizer CEO Albert Bourla said on ABC's "This Week" Sunday it's possible to provide both COVID-19 booster shots as well as doses for people who ...

To help fend off another wave of Covid-19, people will need a fourth dose of vaccine, Pfizer CEO Albert Bourla said Sunday. "Many variants are coming, and Omicron was the first one that was able to ...